Efficacy and Toxicity of Panitumumab After Progression on
Cetuximab and Predictive Value of MiR-31-5p in Metastatic
Wild-type KRAS Colorectal Cancer Patients

J 2016

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients

KISS, Igor; Jitka MLČOCHOVÁ; Zbyněk BORTLÍČEK; Alexandr POPRACH; Jiří DRÁBEK et al.

Základní údaje

Originální název

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients

Název česky

Efektivita a toxicita panitumumabu po progresi na cetuximabu a prediktivní význam MiR-31-5p u pacientů s metastatickým divokým KRAS colorektálním karcinomem

Autoři

Vydání

Anticancer Research, Athens, INT INST ANTICANCER RESEARCH, 2016, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.937

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14740/16:00087634

Organizační jednotka

Středoevropský technologický institut

Klíčová slova česky

KRAS; Metastatický kolorektální karcinom; cetuximab; miR-31-5p; microRNA; panitumumab

Klíčová slova anglicky

KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab

Štítky

rivok

Změněno: 22. 3. 2018 09:20, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

NV16-31765A, projekt VaV

Název: Využití tkáňových/cirkulujících mikroRNA pro predikci léčebné odpovědi a zpřesnění restagingu karcinomu rekta po neoadjuvantní léčbě

TE02000058, projekt VaV

Název: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Akronym: MOLDIMED)

Investor: Technologická agentura ČR, Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu

Citovat

KISS, Igor; Jitka MLČOCHOVÁ; Zbyněk BORTLÍČEK; Alexandr POPRACH; Jiří DRÁBEK; Petra VYCHYTILOVÁ; Marek SVOBODA; Tomáš BÜCHLER; Stanislav BATKO; Aleš RYŠKA; Marian HAJDÚCH a Ondřej SLABÝ. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. Anticancer Research. Athens: INT INST ANTICANCER RESEARCH, 2016, roč. 36, č. 9, s. 4955-4959. ISSN 0250-7005. Dostupné z: https://doi.org/10.21873/anticanres.11063.

@article{1362715,
   author = {Kiss, Igor and Mlčochová, Jitka and Bortlíček, Zbyněk and Poprach, Alexandr and Drábek, Jiří and Vychytilová, Petra and Svoboda, Marek and Büchler, Tomáš and Batko, Stanislav and Ryška, Aleš and Hajdúch, Marian and Slabý, Ondřej},
   article_location = {Athens},
   article_number = {9},
   doi = {https://doi.org/10.21873/anticanres.11063},
   keywords = {KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients},
   url = {http://ar.iiarjournals.org/content/36/9/4955.abstract},
   volume = {36},
   year = {2016}
}

TY  - JOUR
ID  - 1362715
AU  - Kiss, Igor - Mlčochová, Jitka - Bortlíček, Zbyněk - Poprach, Alexandr - Drábek, Jiří - Vychytilová, Petra - Svoboda, Marek - Büchler, Tomáš - Batko, Stanislav - Ryška, Aleš - Hajdúch, Marian - Slabý, Ondřej
PY  - 2016
TI  - Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients
JF  - Anticancer Research
VL  - 36
IS  - 9
SP  - 4955-4959
EP  - 4955-4959
PB  - INT INST ANTICANCER RESEARCH
SN  - 02507005
KW  - KRAS
KW  - Metastatic colorectal cancer
KW  - cetuximab
KW  - miR-31-5p
KW  - microRNA
KW  - panitumumab
UR  - http://ar.iiarjournals.org/content/36/9/4955.abstract
L2  - http://ar.iiarjournals.org/content/36/9/4955.abstract
N2  - Background: In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting. Patients and Methods: In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab. Results: We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab. Conclusion: It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.
ER  -

KISS, Igor; Jitka MLČOCHOVÁ; Zbyněk BORTLÍČEK; Alexandr POPRACH; Jiří DRÁBEK; Petra VYCHYTILOVÁ; Marek SVOBODA; Tomáš BÜCHLER; Stanislav BATKO; Aleš RYŠKA; Marian HAJDÚCH a Ondřej SLABÝ. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients. \textit{Anticancer Research}. Athens: INT INST ANTICANCER RESEARCH, 2016, roč.~36, č.~9, s.~4955-4959. ISSN~0250-7005. Dostupné z: https://doi.org/10.21873/anticanres.11063.

Přehled o publikaci